𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma : A Phase II study

✍ Scribed by Theodore G. Karrison; Nicholas J. Vogelzang


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
52 KB
Volume
86
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Stage I Renal Cell Carcinoma

I read the report by Kinouchi et al., 1 in which they concluded that the tumor grading of renal cell carcinoma was not predictive of the survival of Robson Stage I patients. This does not mean that the three-grading system is worthless; the authors simply showed that the grading system of the Japanese General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma 2 is not useful in the study of Robson Stage I renal cell carcinoma. The Japanese Rule 2 states that renal cell carcinoma should be classified according to the quantitatively dominant grade. Kinouchi et al. 1 omitted this explanation from their article. This "dominant rule" is obviously distinct from the other grading systems, according to which renal tumor grading is decided by the highest grade. 3,4 I am afraid that their report might mislead international readers. The Japanese General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma 2 was made in 1992. Its classification is different from "modern classification" 5-7 and even from the classification criteria of the Armed Forces Institute of Pathology. 3 Kinouchi et al. 1 nicely demonstrated the limitation of the Japanese Rule. 2 I would like to announce that it is time for the Japanese to throw away their old-fashioned Rule. 2 The recently published protocol of the Cancer Committee of the College of American Pathologists 8 has greater possibilities.


πŸ“œ SIMILAR VOLUMES


Intrapleural administration of interleuk
✍ Philippe Astoul; Diane Picat-Joossen; Jean-Regis Viallat; Christian Boutin πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 1 views

## Background: The prognosis associated with malignant pleural mesothelioma (mpm) is poor in spite of surgery, radiotherapy, photodynamic therapy, or chemotherapy. therefore, new therapeutic strategies, including intrapleural immunotherapy, are being investigated. several clinical studies have demo

A phase II study of gemcitabine in patie
✍ Jan P. van Meerbeeck; Paul Baas; Channa Debruyne; Harry J. Groen; Chris Manegold πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo

Cisplatin in combination with irinotecan
✍ Takashi Nakano; A. Philippe Chahinian; Miho Shinjo; Naoki Togawa; Atsushi Tonomu πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 161 KB πŸ‘ 1 views

The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptotheci

Results of a phase II trial of combined
✍ SΓ©bastien Kasseyet; Philippe Astoul; Christian Boutin πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 283 KB πŸ‘ 1 views

## BACKGROUND. Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment. The authors conducted a Phase II trial in which two drugs (etoposide and 5-fluorouracil) were added to the Cancer and Leukemia Group B cisplatin-mitomycin regimen in an effort t

Combined cisplatin, doxorubicin, and mit
✍ Maria Cristina Pennucci; Andrea Ardizzoni; Paolo Pronzato; Marina Fioretti; Clau πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 2 views

and cisplatin (P) yielded an objective response rate of 25% and a subjective response rate of 50% in patients with mesothelioma. In human mesothelioma cell